Efsubaglutide Alfa
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2/3 · Active, not recruiting · Enrollment 1003
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Phase IIb:Efsubaglutide Alfa 5 mg QW | Obesity or overweight | 5 mg | 3 | n/r | n/r |
| Phase IIb:Efsubaglutide Alfa 10 mg QW | Obesity or overweight | 10 mg | 3 | n/r | n/r |
| Phase IIb:Efsubaglutide Alfa 20 mg QW | Obesity or overweight | 20 mg | 3 | n/r | n/r |
| Phase IIb:Efsubaglutide Alfa 20 mg Q2W | Obesity or overweight | 20 mg | 3 | n/r | n/r |
| Phase IIb:Placebo | Obesity or overweight | n/r | 3 | n/r | n/r |
| Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QW | Obesity or overweight | n/r | 3 | n/r | n/r |
| Phase III:Recommended Phase 3 Dose (RP3D) High Dose QW | Obesity or overweight | n/r | 3 | n/r | n/r |
| Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2W | Obesity or overweight | n/r | 3 | n/r | n/r |
| Phase III:Placebo | Obesity or overweight | n/r | 3 | n/r | n/r |